Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment is a research paper published in Journal of Clinical Investigation (2023). On theSindex it has a DataRank of 0.820. It has been cited 235 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.820
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: R00 CA240689
NINDS NIH HHS
Grant: R01 NS110703
NCI NIH HHS
Grant: U19 CA264338
NCI NIH HHS
Grant: P50 CA221747
National Institutes of Health
Grant: 1U19CA264338-01
Advancing treatment and understanding of immunotherapy in glioblastoma
National Institutes of Health
Grant: 1R01NS110703-01A1
MAPK as target of glioma immunoediting by CD8 T-cells, and predictor of response to immunotherapy
National Institutes of Health
Grant: 5R00CA240689-04
Determining the Immunological Consequences of DNA Replication Stress Response Defects in Renal Cells Carcinoma to Improve Immunotherapy Outcomes
National Institutes of Health
Grant: 5P50CA221747-02
SPORE for Translational Approaches to Brain Cancer
FWCI
39.04
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords